INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 456m ago
HOUSE PTR56m ago
SEC 13F56m ago
ROBINHOOD CHAIN56m ago
PM
Corporate insider

Pauls Matthew

DirectorCIK 0001573429

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 5
Max Insider Score20
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$17K
786 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Pelthos Therapeutics Inc.Director · Apr 6, 2026
17
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL
$18K
692 sh
Jul 2, 2026
Jul 7, 2026
traded Jul 2, 2026
+5d
SEC FORM 4

Evidence

17
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$2,572
94 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

20
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,514
415 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$7,926
371 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence